Statins Neuromuscular Adverse Effects

Attardo, Silvia; Musumeci, Olimpia; Velardo, Daniele; Velardo, Daniele

doi:10.3390/ijms23158364

Cited by 57 publications

(44 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few noninvasive techniques exist to accurately diagnose SAMS. 7,18 The most used biomarker is the CK enzyme, commonly employed as a marker of muscle damage. 28 Although our results showed that there were no differences between groups regarding CK values, there is a clinical consensus that alterations may (or may not) appear at any time during statin treatment, with the most common time for CK elevation being between the first and sixth month after the start of treatment.…”

Section: Discussionmentioning

confidence: 99%

Statin exposure during pregnancy promotes neuromuscular junction alterations in postpartum Wistar rats

et al. 2023

View full text Add to dashboard Cite

Introduction/Aims The mechanisms that underlie the pathogenesis of statin‐associated muscle symptoms (SAMS) remain unclear. Pregnancy is associated with increased cholesterol levels. Statins may be useful during pregnancy, but their safety is uncertain. Hence, we investigated the postpartum effects of exposure to rosuvastatin and simvastatin during pregnancy in Wistar rats, targeting the neuromuscular structures. Methods Twenty‐one pregnant Wistar rats were divided into three groups: control (C) treated with vehicle (dimethylsulfoxide + dH20), simvastatin (S) 62.5 mg/kg/day, and rosuvastatin (R) 10 mg/kg/day. Gavage was performed daily from the gestational days 8 to 20. At weaning, the postpartum mother tissues were collected and subjected to morphological and morphometric analysis of the soleus muscle, associated neuromuscular junctions (NMJs), and the sciatic nerve; protein quantification; quantification of the cholesterol and creatine kinase in the serum; and intramuscular collagen analysis. Results An increase in morphometric parameters (area, maximum and minimum diameters, Feret diameter, and minimum Feret) was observed in NMJs from the S and R groups in comparison with the C group, and there was also a loss of common NMJ circularity. The number of myofibers with central nuclei was higher in S (17 ± 3.9, P = .0083) and R (18.86 ± 14.42, P = .0498) than in C (6.8 ± 2.6). Discussion Gestational exposure to statins induced postpartum NMJ morphology alterations in soleus muscle, which may be caused by the remodeling of clusters of nicotinic acetylcholine receptors. This may be associated with the development and progression of SAMS observed in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Statin exposure during pregnancy promotes neuromuscular junction alterations in postpartum Wistar rats

et al. 2023

View full text Add to dashboard Cite

show abstract

“…After days to weeks of stopping the medicine, patients feel better, and their serum CK levels return to normal. The statins considered to have the least side effects on a muscular level are pravastatin and fluvastatin [ 92 , 95 ].…”

Section: Role Of Statins In Managing Dyslipidemiamentioning

confidence: 99%

The Link between Magnesium Supplements and Statin Medication in Dyslipidemic Patients

Nartea

Mitoiu

Ghiorghiu

2023

CIMB

View full text Add to dashboard Cite

Many investigations have discovered a connection between statins and magnesium supplements. On one hand, increasing research suggests that chronic hypomagnesemia may be an important factor in the etiology of some metabolic illnesses, including obesity and overweight, insulin resistance and type 2 diabetes mellitus, hypertension, alterations in lipid metabolism, and low-grade inflammation. Chronic metabolic problems seem to be prevented by a high Mg intake combined with diet and/or supplements. On the other hand, it is known that statins lower the frequency of cardiac events, stroke, and mortality, not by lowering LDL-C, but by the capacity to reduce mevalonate formation. That will enhance endothelial function, inhibit vascular smooth muscle cell proliferation and migration and encourage macrophages to promote plaque stability and regression while reducing inflammation. Taking these factors into consideration, we did an extensive analysis of the relevant literature, comparing the effects of Mg2 and statin medications on lipoproteins and, implicitly, on the key enzymes involved in cholesterol metabolism.

show abstract

“…9 Severe muscle damage, also known as rhabdomyolysis, is a rare but serious side-effect of statins. 10 Furthermore, statin use is associated with lower physical activity among community-dwelling older adults. 11 However, other studies failed to detect consistent changes in muscle contractile function and exercise performance in statin users.…”

Section: Introductionmentioning

confidence: 99%

Statin use impairs muscle strength recovery in post‐stroke patients with sarcopenia

Matsumoto¹,

Yoshimura²,

Nagano³

et al. 2023

Geriatrics Gerontology Int

View full text Add to dashboard Cite

AimThe effects of statins on muscle health are not well established. Therefore, this study investigated the impact of statin use on muscle strength and mass recovery in patients with sarcopenia after stroke.MethodsThis retrospective cohort study included stroke patients with sarcopenia hospitalized between 2015 and 2021 at a post‐acute rehabilitation hospital. Sarcopenia was diagnosed using handgrip strength and skeletal muscle mass index measured using bioelectrical impedance analysis according to the 2019 criteria of the Asian Working Group for Sarcopenia. The study outcomes included handgrip strength and skeletal muscle mass index at hospital discharge. We used multivariate analyses to examine whether statin use was independently associated with the outcomes. Statistical significance was set at P < 0.05.ResultsOf the 586 patients enrolled, 241 (mean age 79.3 years, 44.4% men) presented with sarcopenia and were included in the analysis. Statin use was observed in 61 (25.3%) patients. Statin use was independently negatively associated with handgrip strength at discharge (β = −0.095, P = 0.032), but not with skeletal muscle mass index at discharge (β = 0.019, P = 0.692).ConclusionsStatin use was negatively associated with muscle strength recovery, but not with muscle mass in patients with sarcopenia who underwent rehabilitation after stroke. To maximize outcomes, sufficient consideration is needed for statin use in these patients. Geriatr Gerontol Int 2023; ••: ••–••.

show abstract

Statins Neuromuscular Adverse Effects

Cited by 57 publications

References 89 publications

Statin exposure during pregnancy promotes neuromuscular junction alterations in postpartum Wistar rats

Statin exposure during pregnancy promotes neuromuscular junction alterations in postpartum Wistar rats

The Link between Magnesium Supplements and Statin Medication in Dyslipidemic Patients

Statin use impairs muscle strength recovery in post‐stroke patients with sarcopenia

Contact Info

Product

Resources

About